JANX

Janux Therapeutics, Inc.

JANX · CIK 1817713 · Annual (10-K) · Last 5 years

Financial Trends

Revenue
20212025
Net Income−$114M
20212025
Operating CF−$82M
20212025
Free Cash Flow−$83M
20212025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕
Revenue—————
Cost of Revenue—————
Gross Profit—————
R&D Expense$0.1B$0.1B$0.1B$0.1B$0.0B
SG&A Expense—————
Operating Income$-0.2B$-0.1B$-0.1B$-0.1B$-0.0B
Net Income$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B
EPS (Basic)$-1.83$-1.28$-1.32$-1.52—
EPS (Diluted)$-1.83$-1.28$-1.32$-1.52—

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕
Total Assets$1.0B$1.1B$0.4B$0.4B$0.4B
Current Assets$1.0B$1.0B$0.3B$0.3B$0.4B
Cash & Equivalents$0.1B$0.4B$0.0B$0.1B$0.0B
Total Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$1.0B$1.0B$0.3B$0.3B$0.4B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕
Operating Cash Flow$-0.1B$-0.0B$-0.1B$-0.0B$-0.0B
Investing Cash Flow$-0.3B$-0.3B$-0.0B$0.1B$-0.3B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$0.7B$0.1B$0.0B$0.4B
← Companies